Skip to main content
. 2014 Apr 10;2014:913634. doi: 10.1155/2014/913634

Table 3.

HCC recurrence and survival outcomes.

Response Sorafenib adjuvant therapy 
n = 7
Historical comparison group 
n = 12
P value
Recurrent HCC (%) 2 (29) 9 (75) 0.07
Median recurrent time from OLT (days) 1053 620 0.08
1-year disease-free survival 7 (100) 8 (66)
1-year overall survival (%) 7 (100) 11 (91.6) 0.63
Mean follow-up duration in days (SD) 1125 (310) 840 (483) 0.18